Constitutional Court rejects the second petition seeking the legalization of the medicinal usage of cannabis, arguing that Indonesia has insufficient research and regulation on the matter.
ealth experts have urged the government to take the global scientific evidence on medicinal marijuana more seriously following a Constitutional Court rejection of the latest petition seeking to legalize cannabis for the treatment of disease.
In a ruling issued on Wednesday, the court rejected a petition for a judicial review of the 1976 ratification of the Single Convention on Narcotic Drugs, concluding that there was a lack of comprehensive research evidence to support the medicinal cannabis legalization.
The plaintiffs, Pipit Sri Hartanti and Supardji, are parents of a child with cerebral palsy who sought the substance’s legalization as an alternative treatment to treat the condition.
They brought a new finding from the World Health Organization (WHO) that recommended removing cannabis from Schedule IV of the 1961 Single Convention on Narcotic Drugs, which categorizes substances that have little or no therapeutic purposes.
Cannabis is now included in Schedule I among other substances that are highly addictive, liable to abuse or convertible into addictive drugs in the WHO’s list.
Read also: Mothers of cerebral palsy children fight for medical marijuana
But the court rejected the petitioners, stating that Indonesia had submitted a different position to the WHO’s recommendation, in which the government warned that the harm from using cannabis and related substances outweighed the benefits.
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.
Quickly share this news with your network—keep everyone informed with just a single click!
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Get the best experience—faster access, exclusive features, and a seamless way to stay updated.